Eye on Education

FDA Approves Alcon’s Pataday® as Latest Rx to OTC Switch in Allergy Market

Print this Article | Send to Colleague

Alcon announces it has received FDA approval to sell two eye-allergy itch-relief drops, olopatadine 0.2% and 0.1%, over the counter (OTC) in the U.S.

The solutions will be on the shelves in time for spring allergy season branded as PATADAY Once Daily Relief (formerly PATADAY, 0.2%) and PATADAY Twice Daily Relief (formerly PATANOL, 0.1%). PATADAY Once Daily Relief will come to store shelves as the first and only once-daily eye-itch allergy-relief drop to be available without a prescription in U.S.  

This announcement is important for the 1 in 5 Americans (~66 million) with eye allergies who will now have access to the #1 doctor-prescribed eye-allergy itch-relief ingredient. In addition, eye care professionals can now send patients to their local retailer for prescription-strength relief they know and trust.  

Alcon’s release can be found here and the FDA release can also be found here.


Back to Eye on Education

Share on Facebook Share on Twitter Share on LinkedIn